Natalizumab and immune cells.
McFarland
Henry F
HF
Jacobson
Steven
S
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D006801:Humans; D007157:Immunologic Surveillance / Q000187:drug effects / Q000276:immunology; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D007577:JC Virus / Q000187:drug effects / Q000276:immunology; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced* / Q000276:immunology / Q000821:virology; D008214:Lymphocytes / Q000187:drug effects* / Q000276:immunology; D000069442:Natalizumab; D019562:Viral Load
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab